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troke causes a greater range of disabilities than any other condition. 1 Approximately 5 million people worldwide are left with permanent stroke-related disability every year, 2 making it the most common cause of complex disability in adults. Yet, the full range of functional deficits experienced by stroke survivors is currently not well characterized; few studies have identified the impact of stroke on multiple functional domains.
The WHO International Classification of Functioning categorizes the consequences of a disease into 3 different dimensions: body function impairments, activity limitations, and participation restrictions. 3 Despite these guidelines that capture the complex nature of functioning, our understanding of functional outcome after stroke is mainly limited to activities of daily living, often narrowly defined and evaluated only using the modified Rankin Scale (mRS).
Very few studies examine functional participation limitations. Less than 6% of randomized controlled trials of rehabilitation interventions between 1968 and 2005, 4 only 2% of acute stroke trials between 1955 and 1995, 5 and no acute drug trials between 1980 and 2000 6 assessed participation as an outcome. Activity at 90 days, measured by mRS, remains the most common primary end point in acute trials. 6 Likewise, cognition and mood outcomes-which may be particularly important to patients-are rarely assessed. Stroke patients are at high risk of depression after a stroke 7 ; yet, cognition and mood outcomes are included in only 6% of stroke trials.
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Background and Purpose-Functional outcome after stroke is often only evaluated using the modified Rankin Scale, which primarily assesses activities of daily living. Stroke patients may experience difficulties with social reintegration and mental functions, feel isolated, and experience poor quality of life, even after physical recovery is complete. 
t Good Enough 1689
The current study evaluated the extent of participation restrictions, cognitive impairment, and depressive symptoms in physically recovered (mRS score 0-1) patients to gauge the ability of the mRS to capture stroke-related deficits across multiple domains. We hypothesized that deficits in body function and participation will be prevalent in patients who have recovered in terms of activity as measured by the mRS.
Subjects and Methods
We conducted a follow-up functional outcome assessment of patients over telephone ≈2 to 3 years poststroke. All patients were recruited from the Sunnybrook Stroke Prevention Clinic patient database, which includes consecutive patients referred to the clinic from 2012 to 2014 for stroke or TIA, excluding patients with severe aphasia, patients with severe motor dysfunction, and those who could not speak English. Only those with confirmed stroke, who had a baseline clinic visit within 6 months of their stroke, and who could be contacted within 27±6 months from their baseline visit were included. A total of 270 ischemic and hemorrhagic stroke patients were eligible to participate (see Figure I in the online-only Data Supplement). This study was approved by the Research Ethics Board of Sunnybrook Health Sciences Center.
Follow-Up Assessment
Follow-up assessments were conducted between February 2015 and February 2016. All eligible stroke patients were notified by mail of the study and then contacted by telephone. Based on the WHO ICF (2002), 3 we selected at least 1 outcome measure to evaluate each level of functioning: body function (impairment)-specifically mental function-was assessed using the telephone Montreal Cognitive Assessment (MoCA), 9 psychological body function was assessed using the Patient Health Questionnaire-2, 10 activity (limitation) was assessed using the mRS, 11 and participation (restriction) was evaluated using the Reintegration to Normal Living Index (RNLI). 12 Telephone administration of the MoCA, 13 mRS, 14 and RNLI 15 has been validated. Poor outcome on the mRS was defined as a score ≥2 (indicating inability to return to prestroke level of function), on the MoCA as <26 (indicating mild cognitive impairment), on the PHQ-2 as >0 (indicating the presence of depressive symptoms), and on the RNLI as >0 (indicating the presence of restrictions).
Statistical Analysis
All analyses were performed using IBM SPSS Statistics 22. The frequency of cognitive impairment, participation restrictions, and depression symptoms in good functional outcome patients was determined. Mann-Whitney U tests were conducted to test differences in those with good and poor outcome on the mRS. Significance threshold was set at 0.05.
Results
Of the 270 eligible patients, 15.9% were lost to follow-up and 24.1% declined to participate. At follow-up, 20 patients passed away and 142 were enrolled. Baseline patient characteristics can be found in Table I in the online-only Data Supplement. There was no significant difference in age, education, baseline mRS, baseline depressive symptoms, or baseline cognition between those who enrolled and those who either declined or were lost to follow-up. The average age at follow-up was 67.6 (SD=15.1) years, and average years of education was 14.5 (SD=4.0) years. About half the patients were male (57.0%) and most had an ischemic stroke (89.4%). The average time from stroke to follow-up assessment was 894.2 days (SD=137.7)-≈2 years and 5 months. See Table II in the online-only Data Supplement for data on stroke recurrence, poststroke myocardial infarction, and institutionalization between baseline and follow-up.
Outcome in Physically Stable Patients
Of 142 patients, 96 (67.6%) patients had a favorable (0-1) outcome on the modified Rankin Scale. Of those with a favorable mRS outcome (0-1), 79 and 91 patients completed the MoCA and RNLI, respectively. Forty-three (54.4%) patients were cognitively impaired, and 47 (51.6%) patients had some restrictions in reintegration. Twenty-three (29.5%) patients were both cognitively impaired and had restrictions in reintegration. Follow-up depression symptoms was available for 93 patients; thirty (32.3%) patients endorsed symptoms of depression. Baseline frequency of depressive symptoms and cognitive impairment in good outcome patients can be found in Table III in the onlineonly Data Supplement.
There was no difference in MoCA scores between those who had activity limitations and those who did not (MannWhitney U statistic (U) =916; P=0.110; Table) . Similarly, no significant difference in depressive symptoms was observed (U=1347; P=0.079). Patients with poor mRS outcome had greater participation restrictions (U=661; P<0.001).
Discussion
Stroke affects multiple levels of function and causes disability in complex ways. This study provides insight into the multifaceted nature of functioning after stroke. Reviews of stroke trials have consistently demonstrated the lack of participation, mood and cognition assessments. Our study reveals that a large number of patients with a good mRS outcome continue to be cognitively impaired, unable to socially reintegrate, and experience symptoms of depression. While these patients have recovered in terms of physical disability, returned to their prestroke functional level, and are able to perform activities of daily living independently, they are still experiencing dysfunction on multiple different levels. The lack of emphasis on participation may largely reflect the paucity of established and robust instruments to measure dysfunction in this domain. The mRS is an excellent scale to assess a range of outcomes, including severe disability and death, but it does not provide sufficiently sensitive assessment of cognition, mood, or return to social and occupational functioning. Our study illustrates the need for robust scales to measure these important long-term patient-focused outcomes and integrate them into new clinical trial designs.
This study also demonstrated no difference in depressive symptoms or cognitive impairments between those with good and poor mRS outcome. Given that depression and cognitive impairment are rarely assessed in stroke studies, despite numerous valid and reliable scales for such constructs, these results suggest a significant gap in our understanding of outcome after stroke.
Limitations of this study include attrition and survivor bias, which were mitigated by comparing the baseline characteristics of patients we enrolled and those lost to follow-up. No differences were observed. Nonetheless, patients who survive ≤2 years later are typically those who had mild or moderate strokes. Accordingly, the findings of this study may only apply to mild or moderate stroke patients.
More than half of stroke patients who have made excellent recoveries on the mRS continue to have cognitive impairment and participation restrictions, and one third continue to have depression 2 to 3 years later. The impact of a stroke goes far beyond physical disability. Current definitions of good functional outcome focus on activity limitations, but our results suggest greater attention to multiple levels of recovery is required. The choice of outcome for future poststroke trials must depend on the most important questions to be answered. Ideally, future trials would include aim to assess multiple domains of function in combination with the mRS, either using direct assessments of these key outcomes individually (eg, PHQ for mood, RNLI for reintegration, and MoCA for cognition) or using broader outcome scales such as the AMC Linear Disability Scale or the Boston University Activity Measure for Post-Acute Care that provide information on mobility, activities of daily living, and cognition. Furthermore, the burden and quality of life of caregivers of stroke patients should also be assessed in stroke trials. This study highlights the need for a more holistic approach to outcome assessment that could inform treatment interventions and optimize recovery. 
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